drugset / Trial / NCT00262743

Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

NCT00262743

Phase 1/2 Completed 73 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Green tea extract contains ingredients that may slow the growth of certain cancers. PURPOSE: This phase I/II trial is studying the side effects and best dose of green tea extract and to see how well it works in treating patients with stage 0, stage I, or stage II chronic lymphocytic leukemia (CLL).

Timeline

Start
2005-08
Primary completion
2010-05
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject epigallocatechin-3-gallate Unknown 400 mg Oral
Subject epigallocatechin-3-gallate Unknown 2000 mg Oral

Indications